Q. My mother was prescribed HCTZ for high blood pressure. Her potassium and sodium levels had not been tested in three years, although she saw her doctor for yearly checkups. She ended up in the ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean seated ...

Q. My mother was prescribed HCTZ for high blood pressure. Her potassium and sodium levels had not been tested in three years, although she saw her doctor for yearly checkups. She ended up in the ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated ...

UK Health Agency warns that certain medications increase heat risks. These drugs affect body's cooling mechanisms. Medicines ...

Treating coronary artery disease will involve a personalised treatment plan consisting of lifestyle changes and a combination of medications. Learn more here.